Damora Therapeutics (DMRA) EBIT (2019 - 2026)
Damora Therapeutics (DMRA) reported EBIT of -$30.8 million for Q1 2026, down 1085.49% on a YoY basis from $3.1 million in Q1 2025, and up 84.72% quarter-over-quarter from -$201.7 million in Q4 2025.
Damora Therapeutics (DMRA) EBIT (2019 - 2026) Analysis & Trends
Damora Therapeutics has reported EBIT for 8 years, with the latest figure at -$30.8 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 1085.49% year-over-year to -$30.8 million; the trailing twelve-month figure through Mar 2026 stood at -$239.1 million (down 1150.57% YoY), and the FY2025 full-year result was -$210.9 million, down 847.31% from the prior year.
- EBIT for Q1 2026 stood at -$30.8 million, up from -$201.7 million in the prior quarter.
- The five-year high for EBIT was -$2.6 million in Q1 2025, with the low at -$201.7 million in Q4 2025.
- Historically, EBIT has averaged -$21.5 million across 5 years, with a median of -$8.6 million in 2023.
- Annual changes were most pronounced in 2024 — EBIT jumped 57.45% — and 2025, when it sank 2739.99%.
- Damora Therapeutics' EBIT stood at -$13.5 million in 2022, then jumped by 50.68% to -$6.7 million in 2023, then slipped by 6.46% to -$7.1 million in 2024, then slumped by 2739.99% to -$201.7 million in 2025, then surged by 84.72% to -$30.8 million in 2026.
- The last three EBIT figures came in at -$30.8 million (Q1 2026), -$201.7 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | -30.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.81 Mn |
| Dec 31, 2025 | -201.70 Mn |
| Sep 30, 2025 | -3.16 Mn |
| Jun 30, 2025 | -3.42 Mn |
| Mar 31, 2025 | -2.60 Mn |
| Dec 31, 2024 | -7.10 Mn |
| Sep 30, 2024 | -3.84 Mn |
| Jun 30, 2024 | -5.58 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -6.67 Mn |
| Sep 30, 2023 | -8.58 Mn |
| Jun 30, 2023 | -11.16 Mn |
| Mar 31, 2023 | -13.49 Mn |
| Dec 31, 2022 | -13.53 Mn |
| Sep 30, 2022 | -13.62 Mn |
| Jun 30, 2022 | -17.12 Mn |
| Mar 31, 2022 | -16.94 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -12.94 Mn |
| Jun 30, 2021 | -12.27 Mn |